Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine

J Carrera Montoya; S Collett; D Fernandez Ruiz; L Earnest; MA Edeling; AHY Yap; CY Wong; JP Cooney; KC Davidson; J Roberts; S Rockman; BM Tran; JL McAuley; G Deliyannis; SL Grimley; DFJ Purcell; SA Waters; DI Godfrey; D Hans; M Pellegrini; JM Mackenzie; E Vincan; WR Heath; J Torresi

Journal article

Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle Vaccine

J Carrera Montoya, S Collett, D Fernandez Ruiz, L Earnest, MA Edeling, AHY Yap, CY Wong, JP Cooney, KC Davidson, J Roberts, S Rockman, BM Tran, JL McAuley, G Deliyannis, SL Grimley, DFJ Purcell, SA Waters, DI Godfrey, D Hans, M Pellegrini Show all

Organoids | MDPI AG | Published : 2024

DOI: 10.3390/organoids3010002

Abstract

Existing mRNA COVID-19 vaccines have shown efficacy in reducing severe cases and fatalities. However, their effectiveness against infection caused by emerging SARS-CoV-2 variants has waned considerably, necessitating the development of variant vaccines. Ideally, next-generation vaccines will be capable of eliciting broader and more sustained immune responses to effectively counteract new variants. Additionally, in vitro assays that more closely represent virus neutralization in humans would greatly assist in the analysis of protective vaccine-induced antibody responses. Here, we present findings from a SARS-CoV-2 VLP vaccine encompassing three key structural proteins: Spike (S), Envelope (E)..

View full abstract